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Uveal melanoma is the most common primary intraocular malignancy and the leading primary intraocular disease which can
be fatal in adults. In this paper epidemiologic, pathogenetic, and clinical aspects of uveal melanoma are discussed. Despite the
advance in local ocular treatments, there has been no change in patient survival for three decades. Development of metastases
aﬀects prognosis signiﬁcantly. Current survival rates, factors predictive of metastatic potential and metastatic screening algorithms
arediscussed.Proposedandemergingtreatmentsforuvealmelanomametastasesarealsooverviewed.Currentadvancesingenetics
and cytogenetics have provided a signiﬁcant insight in tumours with high metastatic potential and the molecular mechanisms that
underlie their development. Biopsy of those lesions may prove to be important for prognostication and to allow further research
into genetic mutations and potential new therapeutic targets in the future.
1. Epidemiology
1.1. Incidence. Uveal melanoma is the most common pri-
mary intraocular malignancy and the leading primary
intraoculardiseasewhichcanbefatalinadults.Inthegeneral
population it is uncommon with an incidence of 5.3–10.9
cases per million population per years [1, 2]. There has been
no change in the incidence of uveal melanoma over the past
30 years in the USA [2]. No change in incidence has been
reported for Denmark or Finland. In Sweden, an annual
relative decrease of 1% has been reported [3]. The incidence
rate in black populations has been shown to be low whether
for Africans or African-Americans [1, 4]. The risk is also low
among Asian populations [5] and American populations of
Asian descent [1]. In Europe a north to south decreasing gra-
dient of melanoma incidence among European populations
does support the protective role of pigmentation [6]. Uveal
tract melanoma is usually diagnosed in the sixth decade of
life with a median age of 55 in most series [7]. The incidence
rate has been shown to progressively increase up to the age of
70yearsintheUSA[2].InEurope,similarﬁndingshavebeen
reported with incidence rates increasing with age, peaking at
75 and then reaching a plateau [6].
Most series indicate that both sexes are equally aﬀected
with a slight predominance of males [2, 6, 8]. In a review of
systemic databases, the age of diagnosis is slightly increased
in females (males 59.4, females 61.5) [2].
1.2. Risk Factors. Development of uveal melanoma has
been associated with the presence of ocular or cuta-
neous melanocytic lesions. Ocular lesions include, primarily,
choroidal naevi but also include ocular melanocytosis. The
latter manifests as heterochromia, and a dark eye is due to
a congenital unilateral hyperpigmentation of the episclera
andtheuvealtract.Thecutaneousconditionsassociatedwith
uveal melanoma are familial atypical mole and melanoma
[9], cutaneous melanoma, and oculodermal melanocytosis
(naevus of Ota).
Another host risk factor is a lightly coloured iris, though
there was no deﬁnite association found in regards to prior
nonocular malignancy or hormonal levels [10]. In regard
to environmental factors, weak associations have been made
with sun exposure [11]. Some occupations are believed to
be associated with an increased risk of ocular melanoma
such as arc welders and airline pilots, but this has not been2 Journal of Skin Cancer
Figure 1: Large iris melanoma occupying a signiﬁcant percentage
of the anterior chamber with associated corectopia.
proven. No association has been found with any dietary
habits, smoking, or alcohol consumption [9].
2. Pathogenesis
The development of uveal melanoma has been associated
with early oncogenic mutations. These mutations aﬀect
pathways involved with the regulation of the cell cycle or the
control of cell apoptosis.
2.1. Regulation of the Cell Cycle. The retinoblastoma protein
inhibits cell cycle progression through the G1-S transition
point, and its inactivation by hyperphosphorylation allows
cells to reenter the cell cycle [12].
These mutations appear to involve the RAF/MEK/ERK
pathway. It has been shown in the past that a target of
this pathway, CCND1, responsible for encoding cyclin D1,
is overexpressed in uveal melanomas leading to phospho-
rylation and inactivation of the retinoblastoma tumour
suppressor gene in uveal melanomas [13].
An oncogene mutation aﬀecting this pathway is a muta-
tionofthegenesGNAQandGNA11incodon29.Thesegenes
e n c o d eG N A Q ,t h ea l p h as u b u n i to fah e t e r o t r i m e r i cG T P -
binding protein that couples G-protein-coupled receptor
signaling to the RAF/MEK/ERK and other intracellular
pathways. These pathways are important for melanocyte
homeostasis. In addition, GNAQ is involved in endothelin
signaling which is essential for melanocyte survival early
in development [14]. Activation of GNAQ mimics growth
factor signaling in the RAF/MEK/ERK pathway leading to
transcriptional activation of CCND1.
GNAQmutation wasnoted at 49% of the examined uveal
melanoma postenucleation samples [13] and 45% of biopsy
samples [14, 15], a fact delineating that other mutations
couldalsoberesponsible.GNA11mutationshavebeennoted
at 31.9% of uveal melanoma samples [15].
Another molecular event associated with dysfunction of
the retinoblastoma protein is the inactivation of the INK4A
gene [12].
2.2. Control of Cell Apoptosis. The molecular events that
have been associated with inhibition of apoptosis in uveal
melanoma include inactivation of the p53 pathway [16],
defects in the Bcl-2 pathway [17], and activation of the
prosurvival PI3K-AKT pathway [18].
3.ClinicalFeatures
Iris melanoma appears as a variably pigmented, usually
well-deﬁned mass in the iris stroma and has an 80%
predilection to appear in the inferior portion of the iris
(Figure 1). Size and shape can also be variable. Less common
variables of the iris melanoma are the diﬀuse melanoma,
which causes hyperchromic heterochromia of the iris and
is associated with inﬁltration of the trabecular meshwork,
tapioca melanoma, which has a gelatinous nodular iris
appearance, and the melanoma of the trabecular meshwork
with a ring conﬁguration (Figure 2)[ 19].
Ciliary body melanoma can attain a larger size before it
is recognized clinically. The patient is often asymptomatic.
However,aciliarybodymasscancauselenstiltingoranterior
displacement of the lens which results in an uncorrectable
astigmatism. Signs include dilated episcleral vessels (sentinel
vessels), dense cataract, and in the case of ring melanoma,
raised intraocular pressure. Extrascleral extension is rarely
seen at presentation (Figure 3). Usually the lesion has a
dome-shaped conﬁguration visualised after dilation of the
pupil. Less frequently it can attain a circumferential ring
pattern. It can extend toward the lens and cause localized
cataract (Figure 4), toward the anterior chamber angle and
iris (iridociliary melanoma), or posteriorly into the choroid
(ciliochoroidal melanoma) [7].
Choroidal melanoma may present with visual symptoms
if it is located at the macula; here it will produce micropsia
or visual distortion. Peripheral choroidal melanoma tends to
present with a visual ﬁeld defect or a localised ﬂickering light
corresponding to the location of the mass. If an exudative
retinal detachment is present, the patient may reach a
retinal surgeon ﬁrst before the diagnosis of melanoma is
made. The tumour may be dome or mushroomed shaped.
Diﬀuse choroidal melanoma is a rare aggressive variant.
Small choroidal melanomas often have superﬁcial orange
pigment known as lipofuscin and associated subretinal ﬂuid
(Figure 5). Melanoma is frequently pigmented, and an
amelanotic melanoma must be distinguished from other
simulating lesions. If the tumour is amelanotic, blood vessels
are visible through it and the classical double circula-
tion described with ﬂuorescein angiography may be seen
(Figure 6).
4.Diagnosis
Iris melanoma is usually diagnosed with slit lamp biomi-
croscopy. However ultrasound biomicroscopy can be used
to detect extension of iris melanoma towards the ciliary
body and to diﬀerentiate it from iris cysts [19]. If there
is no evidence of documented growth of the lesion, ﬁne
needle aspiration biopsy (FNAB) or conventional iris biopsy
is sometimes required to diﬀerentiate an iris melanoma from
a suspicious iris naevus.Journal of Skin Cancer 3
(a) (b)
Figure 2: Iris melanoma located in the inferonasal portion of the right eye. Of note the associated corectopia and an episcleral sentinel vessel
were adjacent to the lesion. This lesion extended to the anterior chamber and acquired a ring conﬁguration as shown in gonioscopy.
(a) (b)
Figure 3: Ciliary body melanoma (a) pigmented area with associated sentinel vessel nasally. (b) gonioscopy reveals the underlying lesion.
Ciliary body and choroidal melanoma are typically diag-
nosed with slit lamp biomicroscopy or indirect ophthal-
moscopy. The clinical diagnosis can however be supported
or conﬁrmed with various ancillary studies.
Transillumination is a useful technique to detect ciliary
body and anterior choroidal melanomas. It is also used for
the delineation of the tumour margins intraoperatively. This
technique is performed by placing a ﬁbre-optic point light
source on the ocular surfaceand observing the eye that glows
like a light bulb. In most cases the tumour shows up as a dark
shadow with well-deﬁned margins.
4.1. Fluorescein Angiography. Typical ﬁndings on the ﬂuo-
rescein angiogram include mottled hyperﬂuorescence and
late staining of the lesion. In the case of an amelanotic
melanoma or a large melanoma that has broken through
Bruch’s membrane, the double circulation sign is noted
(Figure7).Inthissign,bothretinal andchoroidalcirculation
are visualized.
4.2. Ultrasonography. A mode ultrasonography demon-
strates medium to low internal reﬂectivity. However most
ocular oncologists use B mode ultrasound which demon-
strates the presence of ultrasonographic hollowness and
choroidal excavation. Not only is it useful for the exami-
nation of a lesion in the presence of a dense cataract or a
vitreous hemorrhage but also it can be helpful in measuring
the elevation of the tumour. This is important not only in
determining the malignant potential of a suspicious lesion
but also in determining the response to treatment of a
malignant melanoma after radiotherapy or laser treatment
[7, 20].
Computed tomography and magnetic resonance imaging
can be used to determine the presence and degree of
extraocular extension, although this is best visualised with
orbital ultrasound. Optical coherence tomography allows the
identiﬁcation of subretinal ﬂuid associated with a suspicious
choroidal naevus [21]. However the clinical importance of
ﬂuid on OCT alone is yet to be determined.
4.3. Risk Factors of Melanocytic Choroidal Lesions. Eight risk
factors for malignant behaviour of melanocytic choroidal
lesions have been identiﬁed [22]. These include: tumour
thickness more than 2mm at initial diagnosis, presence
of associated ﬂuid with the lesion, presence of symptoms,
presence of orange pigment on the surface of the lesion,
location of the lesion close to the margin of the optic
disc (closer than two disc diameters or 3mm), presence
of ultrasonographic hollowness of the lesion at B mode4 Journal of Skin Cancer
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Figure 4: Ciliary body melanoma extending to the lens causing localized cataract.
Figure 5: Typical choroidal melanoma with associated nonrheg-
matogenous retinal detachment.
Figure 6: Amelanotic choroidal melanoma. Choroid vessels are
visible through the tumor.
Figure 7: Fluorescein angiogram of a large amelanotic choroidal
melanoma, notice the double circulation sign with visible leaking
choroidal vessels at the tumor.
ultrasound, absence of a depigmented halo around the
lesion, and absence of drusen. These factors determine
the follow-up schedule of the patient or the initiation of
treatment [21, 22].
5. Treatment
There are many options available for the treatment of
uveal tract melanoma. The principal options are enucle-
ation, plaque radiotherapy, proton beam radiotherapy, and
transpupillary thermotherapy.Journal of Skin Cancer 5
5.1. Enucleation. Enucleation is the traditional method of
treating uveal melanomas. It is generally indicated for
advanced melanomas that occupy most of the intraocular
space or aﬀe c t e de y e sw i t hs e v e r es e c o n d a r yg l a u c o m a .I t
is also indicated for primary tumours that have invaded
the optic nerve. Secondary enucleation is indicated if there
is deﬁnite evidence of recurrence of a tumour initially
treated with alternative treatment modalities (see below).
Preenucleation radiotherapy involving the use of 2000cGy of
external beam radiotherapy for the aﬀected eye and orbit is
no longer advocated as it has not proven to be advantageous
over standard enucleation [23].
In the western world enucleation tends to be performed
with the placement of an orbital implant onto the socket.
There are two major classes of implants: nonporous and
porous implants. Nonporous implants are composed of
silicone,acrylicorPMMA.Themostcommonlyusedporous
implants are composed of hydroxyapatite. The porous
surface allows ﬁbrovascular growth into the implant, which
prevents the extrusion or migration of the implant. Usual
sizes are 18–22mm in diameter.
5.2. Plaque Brachytherapy
5.2.1. Rationale. A radioisotope is a typically man-made
element with an instable nucleus. The loss of an electron
or a neutron is accompanied by the emission of ionising
radiationastheradioisotopedecaystoamorestableelement.
When a radioactive source is placed in against the sclera or
in close proximity to a tumour all structures close to that
source are irradiated. Ionizing radiation is absorbed by the
exposed tissue resulting in the formation of free radicals,
DNA damage, and, eventually, loss of the cell division or cell
death.
5.2.2. Technique. Radioactive plaques are typically round
curvilinear-shaped episcleral discs of varying diameter. The
convex inner surface contains the radioactive source (most
commonly ruthenium-106, iodine-125, or palladium-103).
The concave external surface consists of a heavy metal (e.g.,
silver and gold) to shield structures on the outer surface of
the plaque. The plaque has two or more eyelets (lugs) to
permit suturing to the sclera. Size of the plaque is selected
to maintain a 2mm safety margin around the base of the
tumour. Radiation emitted to the apex of the lesion is
between80and100Gy,whichisconsideredtobetheeﬀective
tumouricidal dose.
The radioactive plaque is removed 2–7 days after inser-
tion when the calculated dose of radiation has been locally
administered.
5.2.3. Complications. The complications of plaque brachy-
therapy include cataract, proliferative radiation retinopathy
(Figure 8), radiation papillopathy (Figure 9), maculopa-
thy, neovascular glaucoma [24], and an exudative tumour
response [25].
Radiation-induced complications occur on average 18–
24 months after plaque treatment [26, 27]. The incidence
ranges from 18 to 43% in diﬀerent series [26, 28]. Clinical
signs of radiation maculopathy have been shown to occur to
up to 75% of patients in the COMS study [29]. Risk factors
for the development of radiation retinopathy include total
radiation dose, proximity of the treated lesion to aﬀected
structures, diabetes mellitus, and younger age [30, 31].
Panretinal photocoagulation can be used for the treatment
of proliferative radiation retinopathy causing regression of
neovascularization in 66% of patients in a recent large series
[31].
5.2.4. Indications. Plaque brachytherapy is indicated for
small choroidal melanomas with evidence of growth, medi-
um-sized uveal melanomas in eyes with useful or salvageable
vision, and large melanomas or larger melanomas if in an
only eye [32, 33].
5.2.5. Results. The COMS Medium-Sized Tumour Trial has
indicatedthatmortalityratesfromiodine-125brachytherapy
and enucleation do not diﬀe rf o ru pt o1 2y e a r sa f t e r
treatment proving the eﬃcacy of radiation in the treatment
of uveal melanoma [34]. Survival rates are 82% at 5 years for
iodine-125 brachytherapy [25] and 84% for ruthenium-106
[35].
The overall tumour recurrence is 10% at 5 years [36].
Treatmentfailurehasbeenassociatedwithlargertumoursize
and posterior extension [36, 37]. The secondary enucleation
rate is 12–17% at 3–5 years followup [35, 38] and is usually
the result of local recurrence or neovascular glaucoma.
49–55% of patients treated with plaque brachytherapy
maintain a best-corrected visual acuity of 6/60 or better and
around 30% have 6/18 visual acuity or better in the treated
eye [35, 38].
5.3. Proton-Beam Radiotherapy
5.3.1. Rationale. Tumour is exposed to a charged proton
beam. Charged protons lose their energy in tissue with
minimal scatter. The energy deposition occurs at the end of
their range (Bragg peak). This property of photons allows a
decreased entry chance through normal tissues. The proton
beam is conformed to adjust to any tumour size [39].
5.3.2. Technique. Four radiopaque tantalum rings are su-
tured to the sclera at the border of the lesion to aid
with tumour localisation with an ocular X-ray. During
the treatment planning, a three-dimensional model of the
tumour is superimposed on the normal eye and a face mask
and collimator are custom designed for the patient. The
ﬁxation angle that will ensure minimal radiation exposure
to lens, fovea, and optic disc and maximal exposure to the
tumour is determined. Standard treatment is fractionated
four times; total dose of 60–70 cobalt Gy equivalents (cGy)
is administered.
5.3.3. Indications. Proton bean radiotherapy is indicated for
all melanomas and in particular larger melanomas up to
24mm in diameter and 14mm in height. Tumours involving6 Journal of Skin Cancer
Figure 8: Amelanotic choroidal malignant melanoma treated with plaque brachytherapy. Follow-up images span a period of 7 years.
Eventually extensive radiation retinopathy developed.
(a)
(b)
Figure 9: Amelanotic malignant choroidal melanoma treated with plaque brachytherapy. Development of radiation papillopathy and
maculopathy one year after treatment.Journal of Skin Cancer 7
the macula, the optic disc, or both are not a contrain-
dication [40]. It is not recommended for very large mela-
nomas that occupy greater than 30% of the ocular volume,
or for tumours with extrascleral extension, large retinal
detachment, or extensive neovascularisation [41].
5.3.4. Results. Most tumours regress for up to 2 years
after treatment. Regression is complete in 15% of patients
(Figure 9). Gragoudas et al. have reported vision loss to
occur in 68% of patients at 5 years after treatment. This
loss has been correlated with proximity of the tumour to
the fovea and the optic disc, the elevation and diameter of
the tumour, and baseline visual acuity [42]. Two additional
risk factors were added in a more recent study [43], namely,
diabetes and retinal detachment with percentages ﬂuctuating
from 16% for low-risk patients to 99% for high-risk patients.
The probability of retaining the eye was 91% at 5 years,
88% at 10 years, and 84% at 15 years after irradiation as
indicated by a large recent series [44]. Complications include
iris neovascularization [41], posterior subcapsular cataract,
radiation maculopathy, and papillopathy (Figures 10 and
11).Survivalrateshavebeenshowntobe86%at5years,77%
at 10 years, and 73% at 15 years after irradiation. Highest
death rates were noted at 3–6 years after treatment [40].
5.4. Transpupillary Thermotherapy. Transpupillary thermo-
therapy (TTT) is a treatment method that utilizes a modiﬁed
diode laser delivery system to induce hyperthermia to the
tumour by delivering heat in the infrared range. Tumour is
heated to a temperature of 60–65 degrees [45]. The sensory
retina is not damaged as much as in laser photocoagulation.
Despite initial results advocating a beneﬁcial eﬀect of TTT
[46], high rates of tumour recurrence have been detected in
23–45% of cases [47, 48].
Recurrences have been attributed to the fact that the
intrascleraltumourcellsdo notabsorbtheemitted heat[49].
Therefore, recurrences have been reported in the orbit due to
extrascleral extension.
Complications of TTT include scotoma, macular trac-
tion, vascular occlusion, and hemorrhage [50].
TTT is currently combined with plaque radiotherapy
[51] or is applied as secondary treatment to local tumour
recurrence after radiotherapy or local resection [52].
6.Metastases
6.1. Survival Rates. Despite the availability of alternative
treatmentmodalities, thesurvivalratesofpatients withuveal
tract melanoma have not changed in 30 years. Cumulative
rates of metastases in the Collaborative Ocular Melanoma
Study at 5 and 10 years after treatment were 25% and
34%, respectively. Common sites of metastases include liver
(90%), lung (24%), and bone (16%) [53, 54]. Patients with
metastases conﬁned to extrahepatic locations have longer
survival (19–28 months) [55]. Median survival for a hepatic
metastasis is 6 months with an estimated survival of 15–
20% at 1 year and 10% at 2 years, irrespective of treatment
[56, 57]. Asymptomatic patients at the time of diagnosis
of metastases have a slightly longer survival in relation to
symptomatic patients [57].
In the case of iris melanoma, distant metastasis to liver
o ro t h e ro r g a n so c c u r si n5 %o fp a t i e n t sa t1 0y e a r so f
followup. The risk is higher if the tumour involves the iris
root and angle and there is elevated intraocular pressure or
extraocular extension [58].
6.2. Predictive Factors of Metastatic Potential
6.2.1.TumourSize. Tumoursizeisoneofthebestparameters
used to predict metastatic disease. According to the COMS
classiﬁcation, a tumour is deﬁned as small if it measures
3mm or less in thickness and less than 10mm in diameter,
as medium-sized if 3–5mm in thickness and 10–15mm in
diameter, and as large if greater than 5mm in thickness and
more than 15mm in diameter. A comparative analysis of
uveal melanoma [59] has indicated that the 5-year survival
rates after enucleation were 84% for small, 68% for medium-
sized, and 47% for large tumours. Another study [60]
indicated that increased tumour thickness increases the risk
of metastasis.
6.2.2.MolecularMarkers. Disseminationoftumourcellsinto
the blood circulation occurs due to lack of lymphatics in
the uveal tract. Haematological markers may, therefore, be
useful for the detection of distant metastases. This rationale
has prompted the research for determination of potential
molecular markers for the early detection of disseminated
tumour cells.
Tyrosinase is an enzyme involved in the synthesis of
melanin by melanocytes and melanoma cells. Serum tyrosi-
nase m-RNA levels have been shown to be increased in
patients with primary uveal melanoma, and they correlate
with metastatic disease. In addition, tyrosinase m-RNA can
be used for the indirect quantiﬁcation of circulating tumour
cells and have been correlared with the dimensions of the
primary tumour [61].
Vascular endothelial growth factor (VEGF) has been
proven to overexpress in uveal melanoma cells. It has
been suggested that this overexpression is indicative of an
angiogenic switch of the uveal melanoma that is associated
with a proliferative stage of the tumour and metastatic
potential [62]. Overexpression of VEGF originates from
abnormal new vessels within the tumour and hypoxia
because of the irregular blood ﬂow. VEGF has been traced
in uveal melanoma cells and in the aqueous humor in eyes
with uveal melanoma [63, 64]. Levels of VEGF have been
associated with the metastatic potential of uveal melanoma
[65], and serum levels are increased in the presence of
micrometastases, and they parallel the extent of liver disease
[62, 65].
Hepatocyte growth factor (HGF) and its receptor c-Met
have been shown to have an important role in the growth of
cellsintheliver.Increasedlevelsofc-Metinprimarytumours
have been associated with a high risk of metastatic potential
[66]. Activation of HGF by c-Met has been shown to induce8 Journal of Skin Cancer
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Figure 10: Large choroidal melanoma of the right eye treated with proton beam radiotherapy. Despite extensive atrophy the lesion is ﬂat.
(a) (b)
Figure 11: Large juxtapapillary lesion treated with proton beam radiotherapy. Extensive radiation retinopathy and papillopathy developed
postoperatively.
increased cell proliferation, downregulate apoptosis, and
increase cell motility and invasive ability [67].
Insulin-like growth factor-1 (IGF-1) is also produced
in the liver, as is HGF. IGF-1 binds to IGF-1R, a surface
membrane glycoprotein. Expression of this molecule has
been associated with worse prognosis in uveal melanoma
[68]. Activation of IGF-1R by binding of circulating IGF-
1 increases cell proliferation, prevents apoptosis, and is
important for integrin adhesion to the extracellular matrix
and invasion of basement membranes. These are essential
steps in the formation of metastasis [69]. Therefore when
metastatic disease is present, serum IGF-1 levels fall [70].
In a recent study, the coexpression of IGF-1 and c-met in
uveal melanoma samples was highly predictive of metastasis
[71]. Despite the promising role of serum molecular markers
in determining metastatic disease at a subclinical level,
their application in metastatic surveillance is limited as
there is a wide variability in the normal range within the
population. For instance, ﬂuctuations of serum IGF-1 within
an individual are more meaningful [70].
6.2.3. Genetic and Cytogenetic Aspects
Chromosomal Alterations. Prescher et al. [72]i nG e r m a n y
were the ﬁrst to describe the chromosome changes seen in
uvealtractmelanomawhichhadnotbeendiscoveredincuta-
neous melanoma. The major chromosome alterations have
been described in chromosomes 3, 6, 8, and 11. However
the most important of these changes is seen in chromosome
3. In short, monosomy 3 (loss of whole of chromosome
3) tends to be found in large uveal tract melanoma in the
ciliary body location. These chromosome changes have been
strongly linked to patient survival. Monosomy 3 is associated
witha5-yearsurvivalofapproximately50%,whereasdisomy
3 has been reported to predict 100% survival [73]. In a
recentlargeseriesof500patientswithuvealmelanoma,those
with monosomy 3 had a signiﬁcantly worse 3-year prognosis
in relation to patients with partial monosomy 3 or disomy
3[ 74]. Interestingly, these chromosomal abnormalities are
signiﬁcantly correlated with the clinical high risk factors
for metastasis in uveal melanoma (such as tumor size at
diagnosis and epithelioid cell histology) [75].
Gene expression proﬁling has been shown to be more
predictiveofmetastaticdeaththanﬂuorescentinsituhybrid-
ization (FISH) analysis of chromosome alterations (12).
Using gene expression proﬁling, melanomas have been
categorized into two groups: Class I and Class II. Class I
denotes tumours with two copies of chromosome 3 (disomy
3) and other beneﬁcial chromosome changes including gain
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copy of chromosome 3 (monosomy 3) and other deleterious
chromosome changes including gain of chromosome 8p
and/ or isochromosome 8p. It is believed that as the tumor
undergoes subsequent growth it either gains a fragment
of chromosome 6p and becomes a less aggressive Class I
melanoma or it loses a copy of chromosome 3 and develops
into a Class II melanoma with high metastatic potential.
Class II tumors have a greater chromosomal aneuploidy and
a signiﬁcantly diﬀerent proliferative capacity as indicated by
the expression of Ki-67 antigen [73].
This signiﬁcant discovery has implications on the subse-
quent management of patients with uveal tract melanoma.
For example, patients with Class II tumours are eligible for
increased metastatic surveillance and entry into adjuvant
treatment trials. At present, the primary surgical manage-
ment of a uveal tract melanoma remains the same whether
the melanoma falls into the category of Class I or Class II.
Gene Alterations. Mutations in genes GNAQ and GNA11
have been associated with the development of uveal mel-
anoma (see Pathogenesis). GNAQ and GNA11 mutations
at codon 209 were encountered in 21.7% and 56.5% of
metastatic uveal melanoma samples, respectively [15]. In the
same series, GNA11mutations were more common in locally
advanced tumours and in tumours of the ciliochoroidal
region. In a recent series of 75 patients [76], GNAQ
mutations were not associated with disease-free survival
despite an occurrence of 53.3%. In addition, no association
was found with chromosome status reinforcing the notion
that these mutations are an early pathogenetic event and
probably are not associated with clinical outcome.
6.3. Metastatic Screening. Currently, here is no universally
accepted algorithm for metastatic screening in patients
with melanoma. In the COMS, chest radiographs and liver
function tests were done every 6 months for at least 5 years.
Despitehighspeciﬁcity(92%),liverfunctiontestshaveasen-
sitivity of less than 15% in the diagnosis of metastatic uveal
melanoma [54]. Serum markers indicative of metastatic
disease have been shown to be alkaline phosphatase and
lactate dehydrogenase [77].
Individual case series have demonstrated that whole-
body F-18-ﬂuoro-2-deoxyglucose positron emission tomog-
raphy/computed tomography imaging is a sensitive modality
in the followup of uveal melanoma patients [78, 79]. The
advantage of this imaging modality is the depiction of
metabolic activity as obtained by F-18-ﬂuoro-2-deoxyglu-
cose positron emission tomography with the combination
of detailed morphologic characteristics from computed
tomography.
Abdominal ultrasonography is also used for metastatic
screening. In a recent study 602 treated patients were
screened with biannual abdominal ultrasound. 63 patients
developed liver metastases detected by ultrasound. 90% of
those patients had metastases in both lobes of the liver,
and 70% had more than 10 lesions. One-third of patients
with liver metastases underwent complete surgical resection.
However, not all metastases could be resected because of the
presence of miliary metastases that were not detectable by
ultrasound [80].
Computed tomography scan has also been used for
staging of a malignancy and the detection of metastases. It
has been demonstrated that the usage of abdominal CT as a
screening tool is often confounded by the presence of benign
lesions as cysts, fatty liver, or lesions that are too small in
size to characterize [81]. In a recent retrospective study of
198 patients, 55% presented with benign lesions and only
3.3% were found to be metastatic lesions. The likelihood of
malignancy increased in relation to the number of lesions
detected.
6.4. Adjuvant Treatment to Prevent Metastatic Disease. In-
terferon-alfa-2a has been used as adjuvant treatment after
the treatment of melanoma in an eﬀort to prevent the
development of metastases as it has been shown to alter
the immune response and inhibit cell proliferation. A large
recent series [82], however, indicated that the development
of metastasis did not diﬀer signiﬁcantly between patients
who received IFN and those who did not [67]. Intra-arterial
hepatic fotemustine has shown promising results in the
treatment of liver metastases from uveal melanoma (see next
section). However, fotemustine did not have a statistically
signiﬁcant survival beneﬁt when used as adjuvant treatment
[83].
No adjuvant therapy is currently available for ocular
melanoma. However, new phase 2 adjuvant treatment trials
a r eu n d e r w a yi nE u r o p ef o ru v e a lt r a c tm e l a n o m a .T h e
London Ocular Oncology Service is collaborating with our
European colleagues in Holland in the use of a dendritic cell
melanoma vaccination (data not yet published) to prevent
the development of metastatic disease in patients at high risk
of metastases.
6.5. Treatment of Metastasis. A broad spectrum of manage-
ment options are available for metastatic disease including
systemic therapies, direct intra-arterial hepatic administra-
tion, and percutaneous hepatic perfusion.
In regard to systemic therapies, the BOLD regimen (ble-
omycin sulfate,vincristine sulfate(Oncovin),lomustine, and
dacarbazine) combined with interferon has shown some re-
sponse in a small percentage of patients [84].
Fotemustine is an alkylating agent with a high ﬁrst pass
liver extraction leading to hepatic concentrations of 8–47
times higher than in normal tissue. This agent has been
evaluated with direct intra-arterial hepatic administration
in 101 patients with liver metastases from uveal melanoma
and has had promising results with a 36% overall response
rate and a median overall survival of 15 months and a
2-year survival rate of 29% [85]. Eﬃcacy of intra-arterial
versus intravenous fotemustine is currently being evaluated
in a Phase III trial by EORTC (European Organization for
Research and Treatment of Cancer).
Another proposed management option is percutaneous
hepatic perfusion with melphalan [50]. This has been shown
toachieveprogression-freediseaseorstabilisationofpatients10 Journal of Skin Cancer
with uveal melanoma metastases, but unfortunately there
was no overall survival beneﬁt [86].
6.5.1. Emerging Treatments for Metastases. In light of the
molecular events associated with the pathogenesis of uveal
melanoma, new therapeutic targets have emerged. Targeting
oftheeﬀectormoleculeMEKintheRAF/MEK/ERKpathway
with a small-molecule inhibitor, AZD6244, has shown
promisingresultsinasmallsubsetofpatientswithmetastatic
uveal melanoma doubling the progression-free survival time
at 114 days versus 50 days for temozolomide. AZD6244
is currently evaluated in a Phase II randomized trial with
temozolomide in patients stratiﬁed with GNAQ/11 status
[87]. Anti-VEGF treatment is currently under experimental
investigation. Bevacizumab has been shown to suppress in
vitro growth and in vivo development of micrometastasis of
ocular melanoma cells in mice [88].
7. Conclusion
Uveal melanoma is the most common primary malignancy
of the eye aﬀecting approximately 500 patients each year
in the UK. Detailed examination and ocular ultrasound
invariably allow the clinician to make the diagnosis without
the need for a diagnostic biopsy.
Successful local treatment options, such as plaque bra-
chytherapy and proton beam radiotherapy, allow for the
preservation of the eye and vision in some cases. Despite the
advance in local ocular treatments, there has been no change
in patient survival for three decades.
Once metastases have developed, prognosis is poor.
However, advances in genetics and cytogenetics have helped
discover more about the tumours with high metastatic
potential and the molecular mechanisms that underlie
their development. In that respect, FNAB or conventional
biopsy may be important for prognostication and to allow
further research into genetic mutations and potential new
therapeutic targets.
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